MRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Mirati Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-2.49. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.22.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -32.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -40.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Mirati Therapeutics's EPS without NRI or its related term are showing as below:
During the past 13 years, Mirati Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 59.20% per year. The lowest was -52.10% per year. And the median was -9.00% per year.
Mirati Therapeutics's EPS (Diluted) for the three months ended in Sep. 2023 was $-2.49. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.22.
Mirati Therapeutics's EPS (Basic) for the three months ended in Sep. 2023 was $-2.49. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.22.
The historical data trend for Mirati Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirati Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
EPS without NRI | Get a 7-Day Free Trial | -3.19 | -5.69 | -7.96 | -11.21 | -13.18 |
Mirati Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EPS without NRI | Get a 7-Day Free Trial | -3.09 | -3.51 | -3.18 | -3.04 | -2.49 |
For the Biotechnology subindustry, Mirati Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Mirati Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirati Therapeutics (NAS:MRTX) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Mirati Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Jamie Christensen | officer: Sr. Vice President, Chief Scie | C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: EVP, Chief Commercial Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
Aaron Ondrey | officer: Interim CFO | 3545 CRAY COURT, SAN DIEGO CA 92121 |
Boxer Capital, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Christopher Fuglesang | other: See remarks | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Shehan Bharatha Dissanayake | other: See remarks | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Aaron I. Davis | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Mva Investors, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Boxer Asset Management Inc. | other: See remarks | CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000 |
Joseph Lewis | other: See remarks | PO BOX N7776, LYFORD BAHAMAS |
Faheem Hasnain | director | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
John B Moriarty | officer: Chief Legal Officer | ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Carol Giltner Gallagher | director | C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Laurie Stelzer | officer: CFO | 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Julie M Cherrington | director | 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
From GuruFocus
By PRNewswire • 08-09-2023
By Marketwired • 10-11-2023
By PRNewswire • 10-10-2023
By GuruFocus Research • 12-15-2023
By GuruFocus Research • 01-12-2024
By Business Wire • 10-09-2023
By PRNewswire • 08-29-2023
By PRNewswire • 10-17-2023
By PRNewswire • 08-09-2023
By PRNewswire • 10-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.